NCT05085990View on ClinicalTrials.gov

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

September 12, 2024

Study Completion Date

September 12, 2024

Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BIOLOGICAL

TARA-002

Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)

Trial Locations (10)

12603

Premier Medical Group of the Hudson Valley, Poughkeepsie

14642

University of Rochester, Department of Urology, Rochester

21204

Chesapeake Urology Research Associates, Baltimore

29572

Carolina Urologic Research Center, Myrtle Beach

32224

Mayo Clinic, Jacksonville

37209

Urology Associates PC, Nashville

55905

Mayo Clinic, Rochester

70112

Tulane Medical Center (TMC) - Clinic/Outpatient Facility, New Orleans

78229

UT Health San Antonio, San Antonio

90089

USC Norris Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Protara Therapeutics

INDUSTRY